Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Inhibrx Biosciences reported that its experimental cancer drug INBRX-106, combined with Merck's Keytruda, achieved a 48.3% response rate in a Phase 2 study, nearly double Keytruda's 26.5% alone. The stock fell 8.8% to $110.45 despite the positive data, with the company planning to expand the study for HPV-positive patients, according to Reuters.
How this was made
The 30-second read
Why it matters
The trial data de‑risks the program but the unexpected price drop creates a short‑term trading signal.
Market read
New Phase 2 results for a biotech can move the stock and influence sector sentiment on immunotherapy.
What to watch
Potential competition from other checkpoint inhibitors and the need for larger Phase 2 data.
Background
Inhibrx (NASDAQ:INBX) is a biotech developing OX40 agonist INBRX-106 for head and neck cancer, partnered with Merck's Keytruda.
Ticker impact
Inhibrx announced Phase 2 data showing INBRX-106 plus Keytruda doubled response rate, causing an 8.8% stock drop.
Potential short‑term downside as investors digest the drop; upside if expansion data confirms efficacy.
New primary disclosure of trial results; market reaction contradicts data, indicating a trading opportunity.
Market effects
Phase 2 success may boost confidence in OX40 immunotherapy targets across biotech.
US biotech sector could see modest rally if expansion data is positive.
Limited to investors focused on oncology immunotherapy pipelines.
Counterpoint
The stock decline may reflect concerns over small sample size and future regulatory hurdles, suggesting caution.
Key entities
- companyInhibrx Biosciences, Inc.
Developer of INBRX-106.
- companyMerck & Co.
Provider of Keytruda, partner in the trial.
